IDH2 and chondrosarcoma: Our results showing the decrease in D-2HG and anti-tumor activity following treatment with AGI-5198 in IDH-mutant chondrosarcoma cells support inclusion of chondrosarcoma patients into ongoing clinical trials of mutant IDH inhibitors for solid tumors.